Published in AIDS Weekly, March 12th, 2001
The researchers found that autologous CD8+ cells were capable, in long-term nonprogressors (LTNPs) and patients responsive to highly active antiretroviral therapy (HAART), of preventing CD4+ cell-harbored virus replication ex vivo.
"CD8+ T-cell-mediated antiviral activity against HIV has been described consistently in infected individuals," explained T.W. Chun and colleagues with the U.S. National Institute of Allergy and Infectious Diseases.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.